Clinical trials: Adenocarcinoma (NOS)
Adenocarcinoma (NOS), Anal Cancer
DESTINY-PANTUMOUR04
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease…
- Conditions
- Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- DP-04 (NCT07124000)
- Testing
- Trastuzumab deruxtecan
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Colon Cancer
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to Capecitabine Chemotherapy in Colon Cancer Treatment
Cancers of the colon and rectum are the third most common cancers in Canadian males and females. The initial therapy of colorectal cancer is surgery to remove the cancer and nearby lymph glands.
- Trial name
- NCT00126867
- Where
- Canada
- Volunteers
- 29 people
- Sponsor
- AHS Cancer Control Alberta
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
This phase II trial studies how well brivanib alaninate works in treating patients with cervical cancer that has come back. Brivanib alaninate may stop the growth of tumor cells by blocking some of the enzymes needed for cell…
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Persistent Disease
- Trial name
- NCT01267253
- Testing
- Brivanib Alaninate, Laboratory Biomarker Analysis
- Where
- 43 sites in United States
- Volunteers
- 31 people
- Sponsor
- Gynecologic Oncology Group
Androgen Receptor Positive, Locally Advanced Salivary Gland Carcinoma
Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
This phase II trial studies how well enzalutamide works in treating patients with androgen receptor positive salivary cancers that have spread from where it started to nearby tissue or lymph nodes (locally advanced) or have…
- Conditions
- Androgen Receptor Positive, Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Salivary Duct Carcinoma
- Trial name
- NCT02749903
- Testing
- enzalutamide
- Where
- 287 sites in United States
- Volunteers
- 46 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Melanoma, Adenocarcinoma
Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
Background: The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from participants' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the…
- Conditions
- Melanoma, Adenocarcinoma, Carcinoma NOS, Neuroendocrine Tumors
- Trial name
- NCT00923026
- Where
- United States
- Volunteers
- 1,150 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Adenocarcinoma
9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
This is a study of the combination of 9 ING-41 (elraglusib) and retifanlimab plus mFOLFIRINOX in patients with pancreatic cancer without prior systemic therapy for advanced disease.
- Trial name
- RiLEY (NCT06896188)
- Testing
- Retifanlimab, Chemotherapy, 9-ING-41
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Anwaar Saeed
Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II
Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
Study participants with primary breast cancer will receive a standard chemotherapy with an anthracycline and a taxane as well as trastuzumab in case of HER2-positive tumors at doses and duration in concordance to current…
- Conditions
- Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer
- Trial name
- GeparSixto (NCT01426880)
- Testing
- Carboplatin, background treatment
- Where
- 3 sites in Germany
- Volunteers
- 595 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer Female NOS, Tubular Breast Cancer Stage II
Denosumab as an add-on Neoadjuvant Treatment (GeparX)
Pharmacologic inhibition of RANKL attenuates the development of mammary carcinoma and inhibits metastatic progression in multiple mouse models.
- Conditions
- Breast Cancer Female NOS, Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Invasive Ductal Breast Cancer
- Trial name
- GeparX (NCT02682693)
- Testing
- Denosumab, nab-Paclitaxel, Epirubicin
- Where
- Germany
- Volunteers
- 780 people
- Sponsor
- GBG Forschungs GmbH
Cervical Adenocarcinoma, Cervical Adenocarcinoma In Situ
Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer
This trial studies the prevalence of anal dysplasia and anal cancer in patients with cervical, vaginal, and vulvar dysplasia and cancer.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenocarcinoma In Situ, Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma, Not Otherwise Specified
- Trial name
- NCT02140021
- Testing
- Biospecimen Collection, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 409 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes
This clinical trial studies glycoprotein and glycan in tissue and blood samples of patients with stage IB-IVA cervical cancer undergoing surgery to remove pelvic and abdominal lymph nodes.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified
- Trial name
- NCT00460356
- Testing
- Laboratory Biomarker Analysis, Lymphadenectomy
- Where
- 18 sites in United States
- Volunteers
- 159 people
- Sponsor
- Gynecologic Oncology Group
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may…
- Conditions
- Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma
- Trial name
- NCT02834013
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 1,007 sites in United States, Guam
- Volunteers
- 798 people
- Sponsor
- National Cancer Institute (NCI)
Hepatoblastoma, Hepatocellular Carcinoma (HCC)
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are…
- Conditions
- Hepatoblastoma, Hepatocellular Carcinoma (HCC), Liver Neoplasms, Metastatic Liver Cancer
- Trial name
- ARYA-2 (NCT04634357)
- Testing
- ET140203 T Cells
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Eureka Therapeutics Inc.
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer
This phase I trial studies the side effects and the best dose of paclitaxel and carboplatin after cisplatin and radiation therapy in treating patients with stage IB-IVA cervical cancer.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7
- Trial name
- NCT01295502
- Testing
- Carboplatin, Cisplatin, External Beam Radiation Therapy
- Where
- 14 sites in United States
- Volunteers
- 45 people
- Sponsor
- Gynecologic Oncology Group
Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Conservative Surgery in Treating Patients With Low-Risk Stage IA2 or IB1 Cervical Cancer
This clinical trial studies conservative surgery in treating patients with low-risk stage IA2 or IB1 cervical cancer. Conservative surgery is a less invasive type of surgery for early stage cervical cancer and may have fewer side…
- Conditions
- Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IA2 Cervical Cancer AJCC v6 and v7, Stage IB1 Cervical Cancer AJCC v6 and v7
- Trial name
- NCT01048853
- Testing
- Lymph Node Mapping, Quality-of-Life Assessment, Salpingo-Oophorectomy
- Where
- 20 sites in United States, Argentina and 6 more
- Volunteers
- 137 people
- Sponsor
- M.D. Anderson Cancer Center
Human Papillomavirus Infection, Cervical Cancer
Primary Cervical Cancer Screening by Self-sampling HPV Test
Cervical cancer seriously threatens women's health and HPV infection is the main cause of cervical cancer. Traditionally, Cervical cancer screening is based on cervical exfoliated cell samples collected by health care provider…
- Conditions
- Human Papillomavirus Infection, Cervical Cancer, Negative For Intraepithelial Lesion Or Malignancy, Atypical Squamous Cells of Undetermined Significance
- Trial name
- PREVENT (NCT05613283)
- Where
- 6 sites in China
- Volunteers
- 17,875 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer
This phase II trial studies the side effects and how well vaccine therapy works in treating patients with cervical cancer that does not go to remission despite treatment (persistent) or has come back (recurrent).
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma
- Trial name
- NCT01266460
- Testing
- Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001, Laboratory Biomarker Analysis
- Where
- 24 sites in United States
- Volunteers
- 54 people
- Sponsor
- Gynecologic Oncology Group
Esophageal Cancer, Gastric Cancer
Irinotecan in Treating Patients With Advanced Cancer of the Stomach
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have advanced…
- Trial name
- NCT00003137
- Testing
- irinotecan hydrochloride
- Where
- 19 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-small-cell Lung Cancer
Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)
The goal of this clinical research study is to compare 2 types of radiotherapy, stereotactic body photon radiotherapy (SBRT) and stereotactic body proton radiotherapy (SBPT).
- Trial name
- NCT01511081
- Testing
- SBRT (stereotactic body radiotherapy), SBPT (stereotactic body proton therapy)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women
This phase II trial studies how well standard chemotherapy and radiation therapy given with or without paclitaxel and carboplatin work in treating human immunodeficiency virus (HIV)-positive women with cervical cancer that has…
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, FIGO Stage IIB Cervix Carcinoma
- Trial name
- NCT03834571
- Testing
- Carboplatin, Cisplatin, Paclitaxel
- Where
- 3 sites in South Africa, Zimbabwe
- Sponsor
- AIDS Malignancy Consortium
Esophageal Adenocarcinoma, Esophagus SCC
Multiorgan Metabolic Imaging Response Assessment of Abemaciclib
Open-label, phase II, basket trial. This trial is a screening program for abemaciclib efficacy in multiple platinum-resistant tumour types by using metabolic imaging (PERCIST) and RECIST v1.1 criteria.
- Conditions
- Esophageal Adenocarcinoma, Esophagus SCC, Cholangiocarcinoma, Urothelial/Bladder Cancer, Nos
- Trial name
- MiMe-A (NCT03339843)
- Testing
- Abemaciclib
- Where
- 11 sites in Belgium, France
- Volunteers
- 85 people
- Sponsor
- Jules Bordet Institute